
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Click the title above to open the Pharmaceutical Technology August 2017 issue in an interactive PDF format.
over 9 years ago
Using QbD in Topical Drug Manufacturingover 9 years ago
Targeting Drug Delivery with ADCsover 9 years ago
Optimizing Cell-Culture Mediaover 9 years ago
Gottlieb Tackles Opioids, Drug Costs, and Innovationover 9 years ago
Larger Peristaltic Pumps Allow Scale-Upover 9 years ago
A Look at Batch Record Reviewover 9 years ago
Drying, Granulating, and Coating System Offers Modularityover 9 years ago
Heavy-Duty Multi-Agitator Mixerover 9 years ago
CDMOs: New Administration, New Frontierover 9 years ago
Single-Use Systems Expand Scale of Chromatography





